Tara Gomes


Scientist, Li Ka Shing Knowledge Institute


Please note Dr. Gomes will not be accepting summer students in 2019.

Dr. Tara Gomes is an epidemiologist and Principal Investigator of the Ontario Drug Policy Research Network (ODPRN), a provincial network of researchers with expertise in pharmaceutical utilization, outcomes and policy who rapidly conduct research for drug decision-makers in Ontario and across Canada.  She is also a Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital and the Institute for Clinical Evaluative Sciences and an assistant professor at the University of Toronto.  Her research is focused on pharmacoepidemiology, drug safety and drug policy research leveraging large, administrative databases, and she has published over 125 peer-reviewed articles and over 50 policy reports in this area.

Dr. Gomes has worked closely with the Ontario Ministry of Health and Long-Term Care and the Canadian Network for Observational Drug Effect Studies (CNODES) to develop evidence to inform policies related to opioid use and abuse in Ontario and more broadly across Canada.  She has also served as an expert for the US Food and Drug Administration and the US Department of Transportation in discussions related to opioid policies and regulations. In 2014, the ODPRN was awarded the Institute for Public Administration of Canada’s Bronze Public Sector Leadership Award in Health and Education.

Recent Publications

  1. Mamdani, M, Gomes, T, Greaves, S, Manji, S, Juurlink, DN, Tadrous, M et al.. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. JAMA Netw Open. 2019;2 (10):e1913304. doi: 10.1001/jamanetworkopen.2019.13304. PubMed PMID:31617924 .
  2. Persaud, N, Bedard, M, Boozary, AS, Glazier, RH, Gomes, T, Hwang, SW et al.. Effect on Treatment Adherence of Distributing Essential Medicines at No Charge: The CLEAN Meds Randomized Clinical Trial. JAMA Intern Med. 2019; :. doi: 10.1001/jamainternmed.2019.4472. PubMed PMID:31589276 .
  3. Leece, P, Chen, C, Manson, H, Orkin, AM, Schwartz, B, Juurlink, DN et al.. One-Year Mortality After Emergency Department Visit for Nonfatal Opioid Poisoning: A Population-Based Analysis. Ann Emerg Med. 2019; :. doi: 10.1016/j.annemergmed.2019.07.021. PubMed PMID:31561997 .
  4. Iaboni, A, Campitelli, MA, Bronskill, SE, Diong, C, Kumar, M, Maclagan, LC et al.. Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. CMAJ Open. ;7 (3):E582-E589. doi: 10.9778/cmajo.20190052. PubMed PMID:31551235 .
  5. Muratov, S, Lee, J, Holbrook, A, Paterson, JM, Guertin, JR, Mbuagbaw, L et al.. Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. CMAJ Open. ;7 (3):E537-E545. doi: 10.9778/cmajo.20180185. PubMed PMID:31451447 PubMed Central PMC6710084.
  6. Xu, Y, Schulman, S, Dowlatshahi, D, Holbrook, AM, Simpson, CS, Shepherd, LE et al.. Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thromb. Res. 2019;182 :12-19. doi: 10.1016/j.thromres.2019.07.026. PubMed PMID:31434018 .
  7. Gomes, T, Khuu, W, Tadrous, M, Vigod, S, Cobigo, V, Lunsky, Y et al.. Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. BMJ Open. 2019;9 (7):e028125. doi: 10.1136/bmjopen-2018-028125. PubMed PMID:31366646 PubMed Central PMC6677990.
  8. Tadrous, M, Matta, R, Greaves, S, Herschorn, S, Mamdani, MM, Juurlink, DN et al.. Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older-A Population-Based Cohort Study. JAMA Intern Med. 2019; :. doi: 10.1001/jamainternmed.2019.2011. PubMed PMID:31305875 PubMed Central PMC6632155.
  9. Spithoff, S, Kiran, T, Khuu, W, Kahan, M, Guan, Q, Tadrous, M et al.. Quality of primary care among individuals receiving treatment for opioid use disorder. Can Fam Physician. 2019;65 (5):343-351. . PubMed PMID:31088874 PubMed Central PMC6516690.
  10. Martins, D, Khuu, W, Tadrous, M, Juurlink, DN, Mamdani, MM, Paterson, JM et al.. Impact of delisting high-strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. Pharmacoepidemiol Drug Saf. 2019;28 (5):726-733. doi: 10.1002/pds.4764. PubMed PMID:30873707 PubMed Central PMC6518867.
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
  • Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto
  • Scientist, Institute for Clinical Evaluative Sciences
  • Principal Investigator, Ontario Drug Policy Research Network